Main Content

Publications of subproject TP8

Clinical phase Ib trial: T cell-targeted immunotherapy of pemphigus vulgaris

Original papers

Pollmann R, Walter E, Schmidt T, Waschke J, Hertl M, Möbs C, Eming R. Identification of autoreactive B cell subpopulations in peripheral blood of autoimmune patients with pemphigus. Front Immunol. 2019. 10:1375. https://doi.org/10.3389/fimmu.2019.01375

Solimani F, Pollmann R, Schmidt T, Schmidt A, Savai R, Zheng X, Mühlenbein S, Pickert J, Eubel V, Möbs C, Eming R, Hertl M. Therapeutic targeting of Th17/Tc17 cells leads to clinical improvement of lichen planus. Front Immunol. 2019. 10. https://doi.org/10.3389/fimmu.2019.01808

Kugelmann D, Rötzer V, Walter E, Egu DT, Fuchs MT, Vielmuth F, Vargas-Robles H, Schnoor M, Hertl M, Eming R, Rottner K, Schmidt A, Spindler V, Waschke J. Role of Src and Cortactin in Pemphigus Skin Blistering. Front Immunol. 2019 Apr 4;10:626. https://doi.org/10.3389/fimmu.2019.00626

Solimani F, Maglie R, Pollmann R, Schmidt T, Schmidt A, Ishii N, Tackenberg B, Pickert J, Kirschbaum A, Hashimoto T, Hertl M. Thymoma-associated paraneoplastic autoimmune multiorgan syndrome – from pemphigus to lichenoid dermatitis. Front Immunol. 2019. Case Report. https://doi.org/10.3389/fimmu.2019.01413

  • Inhalt ausklappen Inhalt einklappen Published before 2019Published before 2019

    Amber KT, Maglie R, Solimani F, Eming R, Hertl M. Targeted Therapies for Autoimmune Bullous Diseases: Current Status. Drugs. 2018 Oct;78(15):1527-1548. doi:10.1007/s40265-018-0976-5.

    Schmidt T, Solimani F, Pollmann R, Stein R, Schmidt A, Stulberg I, Kühn K, Eming R, Eubel V, Kind P, Arweiler N, Sitaru C, Hertl M. TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. J Allergy Clin Immunol. 2018 Aug;142(2):669-672.e7. https://doi.org/10.1016/j.jaci.2018.02.044

    Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: A Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Clin Rev Allergy Immunol. 2018 Feb;54(1):1-25. doi:10.1007/s12016-017-8662-z.

    Walter E, Vielmuth F, Rotkopf L, Sárdy M, Horváth ON, Goebeler M, Schmidt E, Eming R, Hertl M, Spindler V, Waschke J. Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus. Sci Rep. 2017 Jun 15;7(1):3579. doi:10.1038/s41598-017-03697-7

    Carambia C, Freund B, Schwinge D, Bruns OT, Salmen SC, Ittrich H, Reimer R, Heine M, Huber S, Waurisch C, Eychmüller A, Wraith DC, Korn T, Nielsen P, Weller H, Schramm C, Lüth S, Lohse AW, Heeren J, Herkel J. Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice. J Hepatol. 2015, 62: 1349-1356. https://doi.org/10.1016/j.jhep.2015.01.006

    Eming R, Sticherling M, Hofmann S C, Hunzelmann N, Kern J S, Kramer H, ... & Hertl M. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015 13(8), 833-844. https://doi.org/10.1111/ddg.12606

    Eming R, Hennerici T, Bäcklund J, Feliciani C, Visconti KC, Willenborg S, Schmidt J, Holmdahl R, Sonderstrup G, Hertl M. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells. J Immunol. 2014 193(9):4391-9. https://doi.org/10.4049/jimmunol.1401081

    Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S, Yayli S, Mimouni D, Borradori L, Feliciani C, Ioannides D, Joly P, Kowalewski C, Zambruno G, Zillikens D, Jonkman MF. Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). JEADV. 2014. https://doi.org/10.1111/jdv.12772

    Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008; 128: 2850–8. https://doi.org/10.1038/jid.2008.172

    Veldman CM, Gebhard KL, Uter W, Wassmuth R, Grötzinger J, Schultz E, Hertl M. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol. 2004a Mar 15;172(6):3883-92. https://doi.org/10.4049/jimmunol.172.6.3883

    Veldman C, Höhne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol. 2004b May 15;172(10):6468-75. https://doi.org/10.4049/jimmunol.172.10.6468

    Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol. 2003 Jan 1;170(1):635-42. https://doi.org/10.4049/jimmunol.170.1.635

Review articles

Didona D, Maglie R, Eming R, Hertl M. Pemphigus: current and future therapeutic strategies. Front Immunol. *shared authorship. https://doi.org/10.3389/fimmu.2019.01418

Spindler V, Eming R, Schmidt E, Amagai M, Grando S, Jonkman MF, Kowalczyk AP, Müller EJ, Payne AS, Pincelli C, Sinha AA, Sprecher E, Zillikens D*, Hertl M*, Waschke J*. Mechanisms Causing Loss of Keratinocyte Cohesion in Pemphigus. J Invest Dermatol. 2018 Jan;138(1):32-37. https://doi.org/10.1016/j.jid.2017.06.022